BKM120 (NVP-BKM120, Buparlisib) 化学構造
分子量: 410.39

高品質保証

文献中の引用(34)

カスタマーフィードバック(3)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • BKM120 (NVP-BKM120, Buparlisib)のメカニズム

製品の説明

生物活性

製品説明 BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。
ターゲット p110α p110β p110δ p110γ
IC50 52-99 nM 166 nM 116 nM 262 nM [1]
In vitro試験 BKM120 is not sensitive to Class III and Class IV PI3K's or PI4K. NVP-BKM120 shows great antiproliferation activity to PI3K deregulated cell lines including A2780, U87MG, MCF7 and DU145 with GI50 of 0.1-0.7 nM. [1] BKM120 induces multiple myeloma cells (ARP1, ARK, MM.1S, MM1.R and U266) apoptosis, which results in increased G1-phase cells and decreased S-phase cells. BKM120 induced CD138+ primary MM cell apoptosis and has significant lower cytotoxicity toward CD138− stromal cells. BKM120 exposure could cause upregulation of BimS and downregulation of XIAP. [2] BKM120 demonstrates antiproliferative activity in human gastric cancer cell lines by decreasing mTOR downstream signaling. BKM120 could increase either p-ERK or p-STAT3 in KRAS mutant gastric cancer cells. Combination with STAT3 blockade, BKM120 shows a synergism in cells harboring mutated KRAS by inducing apoptosis, but not in KRAS wild-type cells. [3] A recent study shows that BKM120 shows differential forms of cell death on the basis of p53 status of the cells with p53 wild-type cells undergoing apoptotic cell death and p53 mutant/deleted cells having a mitotic catastrophe cell death. BKM120 mediates mitotic catastrophe mainly through Aurora B kinase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF7 M1PoRWN6fG:2b4jpZ{BCe3OjeR?= Mn3LO|IhcA>? MlHUSG1UVw>? NVfM[W17S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCneIDy[ZN{cW6pIGDJN2tidHCqYTDFOVQ2UyCvdYThcpQhf2m2aDDHTVUxKG:oIECuNFAxOTV6IN88US=> NHfsUFQzPDlyMEK2Oi=>
DU145 MnzER5l1d3SxeHnjJGF{e2G7 M{LBVFczKGh? NH7PUG5FVVOR MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEyNQkGgcZV1[W62IIfpeIghT0l3MDDv[kAxNjByMESzOUDPxE1? MXuyOFkxODJ4Nh?=
A2780 M2nEemN6fG:2b4jpZ{BCe3OjeR?= MVS3NkBp NGTqXWVFVVOR M1\tVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY{PSEQvF2= M4XHVlI1QTByMk[2
U87MG MmnJR5l1d3SxeHnjJGF{e2G7 NEHNNJo4OiCq M2C3[WROW09? M4D2RmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCWRV6t[IVncWOrZX70JIh2dWGwIGW4O21IKGOnbHzzJJdqfGhiR1m1NEBw\iByLkCwNFY6QCEQvF2= NH\pdG0zPDlyMEK2Oi=>
A2780 M4f4dmZ2dmO2aX;uJGF{e2G7 M3;LeFEhcA>? Ml;vSG1UVw>? M4L6VmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6wOVUh|ryP M3S4WVI1QTByMk[2
DU145 M4LnZ2Z2dmO2aX;uJGF{e2G7 M1XaSFEhcA>? MnLvSG1UVw>? Ml;ITY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1? M4DGbVI1QTByMk[2
A2780 MoLiSpVv[3Srb36gRZN{[Xl? M1e5ZVEhcA>? NFThOJNFVVOR MoGxTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJIlvKFCWRV6t[IVncWOrZX70JIh2dWGwIFGyO|gxKGOnbHzzJJdqfGhiRVO1NEBw\iByLkC3OEDPxE1? NY\RfYpGOjR7MECyOlY>
MCF7 MkTTSpVv[3Srb36gRZN{[Xl? NYnTOXVwOSCq M3T6[WROW09? MXfJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0> MmXoNlQ6ODB{Nk[=
U87MG MV7GeY5kfGmxbjDBd5NigQ>? M3fo[|EhcA>? MYDEUXNQ NVzHZotIUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= NYTVNZd5OjR7MECyOlY>
A2780 NYC1N|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7FTYFxPzJiaB?= NIXkNIVFVVOR MnjRSWM2OD1yLkWyJO69VQ>? MWKyOFkxODJ4Nh?=
SKMES-1 M4fiU2N6fG:2b4jpZ{BCe3OjeR?= MoHUNUDPxE1? NFzpSWM4OiCq MmPPTY5lfWOnczDj[YxtKGSnYYTo NF;wWIIzPjBzM{OxPC=>
H596 NIDTRppHfW6ldHnvckBCe3OjeR?= NXLXS5dpOSEQvF2= NGPXS4pKdXCjaYLzJINmdGxibXnndoF1cW:w MnW0NlYxOTN|MUi=
HCC2450 MmPJSpVv[3Srb36gRZN{[Xl? MVuxJO69VQ>? MlXMTY1x[Wm{czDj[YxtKGmwdnHzbY9v MWiyOlAyOzNzOB?=
A549 NETpO4RHfW6ldHnvckBCe3OjeR?= MV21NFAhdk1? MUC0PEBp NU\hdpBITE2VTx?= M2j3V2lvcGmkaYTzJGFsfCCjY4TpeoF1cW:w NWfIe4JtOjV7M{eyPVk>
A549 NGrlTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxJO69VQ>? NUnBZYc1PzJiaB?= Mn;iSG1UVw>? NV;1VmVqUW6qaXLpeJMh[2WubDDndo94fGh? NX\EXZlUOjV7M{eyPVk>
H522 MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT6U2gyKM7:TR?= M2PKflczKGh? NYfVVWxlTE2VTx?= NWKzWGhEUW6qaXLpeJMh[2WubDDndo94fGh? MlrENlU6Ozd{OUm=
LNCaP NF\5bpNHfW6ldHnvckBCe3OjeR?= MUKxJO69VQ>? M3q3Z3N2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NFGwOYEzPTN4MEe5PS=>
LNCaP95 NIrTRlZHfW6ldHnvckBCe3OjeR?= M37oclEh|ryP NH;UWG5UfXCycnXzd4V{KHBvQVvUJIxmfmWucx?= NF3ofGkzPTN4MEe5PS=>
HCT-15 NWXjNlU{SXCxdH;zbZMhSXO|YYm= M1nFcFExKM7:TR?= NUDmR2FQPDhiaB?= NEDiWGlFVVOR M2XHNGlv\HWlZYOgZZBweHSxc3nzJIlvKEiFVD2xOUBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M{H6[|I2OTV{MkS1
HCT-116 M{LieGFxd3Sxc3nzJGF{e2G7 M2nwN|ExKM7:TR?= NHXwTWw1QCCq MWXEUXNQ Mmm2TY5lfWOnczDhdI9xfG:|aYOgbY4hUEOWLUGxOkBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w M1;XO|I2OTV{MkS1
NCI-H460 M2riWGFxd3Sxc3nzJGF{e2G7 MnvwNVAh|ryP NIjXUHY1QCCq MofZSG1UVw>? Ml3YTY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MXOyOVE2OjJ2NR?=
SKOV-3 NYnldmR6SXCxdH;zbZMhSXO|YYm= M13Rd|ExKM7:TR?= MX:0PEBp Mn75SG1UVw>? NEDUVlBKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCVS1;WMVMh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= M1Lx[|I2OTV{MkS1
BSY-1 NIH6Wm5CeG:2b4Ppd{BCe3OjeR?= NHjWOG8yOCEQvF2= NGHSVVI1QCCq NVzaSnhUTE2VTx?= MXnJcoR2[2W|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT|NESSCqb4TzdI91KG23dHH0bY9v M{jqe|I2OTV{MkS1
MKN-1 M4n6[GFxd3Sxc3nzJGF{e2G7 NIHxN5AyOCEQvF2= NYnLUW5CPDhiaB?= M{jPe2ROW09? Ml;QTY5lfWOnczDhdI9xfG:|aYOgbY4hVUuQLUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NEXFWo8zPTF3MkK0OS=>
NCI-H522 MWTBdI91d3OrczDBd5NigQ>? MYWxNEDPxE1? MkHzOFghcA>? NIHOUI9FVVOR NF\0S|FKdmS3Y3XzJIFxd3C2b4Ppdy=> M1jCfFI2OTV{MkS1
OVCAR-3 NYTXeHN5SXCxdH;zbZMhSXO|YYm= NY\ocop2OTBizszN MnfCOFghcA>? NHn1d3lFVVOR NGXzfXpKdmS3Y3XzJIFxd3C2b4Ppdy=> NIfBVI8zPTF3MkK0OS=>
HBC-5 MkLmRZBwfG:|aYOgRZN{[Xl? MYCxNEDPxE1? MmP1OFghcA>? NF;JfnBFVVOR NHvPZ4RKdmS3Y3XzJIFxd3C2b4Ppdy=> MYeyOVE2OjJ2NR?=
RXF-631L MU\BdI91d3OrczDBd5NigQ>? MmfYNVAh|ryP Ml6yOFghcA>? NGXYWmxFVVOR NI\pOo1KdmS3Y3XzJIFxd3C2b4Ppdy=> NGriUmszPTF3MkK0OS=>
MKN-45 MlPqRZBwfG:|aYOgRZN{[Xl? NVTUWIZoOTBizszN NXT4UmxSPDhiaB?= MnHwSG1UVw>? NH;GUVRKdmS3Y3XzJIFxd3C2b4Ppdy=> M3vLZVI2OTV{MkS1
BON-1 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjHcpc2ODBibl2= MWmxNEBl NWHlOo5UTE2VTx?= MY\Jcohq[mm2czDj[YxtKGe{b4f0bC=> NYHPWIJCOjVyMk[yPVI>
BON-1 M2fhOmZ2dmO2aX;uJGF{e2G7 M3;je|UxOCCwTR?= M2rRR|QhcA>? MVzEUXNQ NXPTb3VnUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> MUGyOVAzPjJ7Mh?=
QGP-1 NIW1dHZHfW6ldHnvckBCe3OjeR?= NYPie2d[PTByIH7N NFrqPIs1KGh? MVfEUXNQ NW\WeXFKUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> NGXOfJMzPTB{NkK5Ni=>
Huh7 NX7DOol7TnWwY4Tpc44hSXO|YYm= M3;PRVEh|ryP NFL6PJMyKGh? NW\zZlltTE2VTx?= NF;JVmFKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuWIHH0JHNmejR5NB?= MlHVNlUxODR2MEO=
BNL NInwZopHfW6ldHnvckBCe3OjeR?= M2HD[VEh|ryP NYrBV4lVOSCq MkjDSG1UVw>? MmmyTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3 NELKXmUzPTByNESwNy=>
MDA-MB-175 NITXZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPvOoQyKM7:TR?= Ml;HOUBl NH\zNWVFVVOR NXLINllYUUN3MEyxJO69VQ>? MXmyOFg4QTd7Nh?=
MDA-MB-134 NFLpbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;KNWoyKM7:TR?= NVfr[lR6PSCm MoDoSG1UVw>? NYjIdmFWUUN3MEyxJO69VQ>? NHXG[G4zPDh5OUe5Oi=>
HCC1500 NGj3WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvUNUDPxE1? Mn3ROUBl M2KyfmROW09? NIfiR4JKSzVyPEGg{txO NVLUUIt7OjR6N{m3PVY>
EFM-19 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zq[lEh|ryP Mm[xOUBl Mn\3SG1UVw>? M2ra[mlEPTB:MTFOwG0> M3PHRlI1QDd7N{m2
ZR-75-30 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPkfoFjOSEQvF2= NXzEeHljPSCm Mk[ySG1UVw>? NEPocZZKSzVyPEGg{txO MlPENlQ5Pzl5OU[=
MDA-MB-361 M2GxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPURo0yKM7:TR?= NXv2NWtyPSCm MX\EUXNQ M{XibGlEPTB:MTFOwG0> MY[yOFg4QTd7Nh?=
T-47D MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxJO69VQ>? MnrQOUBl MYjEUXNQ NF7GZnVKSzVyPEGg{txO M{fDXlI1QDd7N{m2
SK-BR-3 NHWxflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn3NUDPxE1? MnjPOUBl MUTEUXNQ M3jTSWlEPTB:MTFOwG0> NV;DcVVJOjR6N{m3PVY>
UACC-732 M4PTU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxJO69VQ>? NET2[VI2KGR? M4[4fmROW09? NF[zdJhKSzVyPEGg{txO NFT5[lgzPDh5OUe5Oi=>
BT-474 NWDIRVZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPBc4wyKM7:TR?= MorNOUBl NWjQS5hnTE2VTx?= NXHu[ZBGUUN3MEyxJO69VQ>? NG\je4kzPDh5OUe5Oi=>
HCC202 M2q3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmxJO69VQ>? M3fTPFUh\A>? NUTEfmt{TE2VTx?= NUDoNnZMUUN3MEyxJO69VQ>? Mk\sNlQ5Pzl5OU[=
MCF7 M2jlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXINUDPxE1? NXS0NXJLPSCm Mo\3SG1UVw>? MWLJR|UxRDFizszN MUGyOFg4QTd7Nh?=
MDA-MB-415 M1zFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XLTVEh|ryP MnLZOUBl MUPEUXNQ NIDydGJKSzVyPEGg{txO NFX0N3kzPDh5OUe5Oi=>
MDA-MB-453 M4LoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDjNUDPxE1? M3XtZlUh\A>? MWLEUXNQ MXnJR|UxRDFizszN M{nVXVI1QDd7N{m2
ZR-75-1 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[zUnYyKM7:TR?= MUm1JIQ> MlLlSG1UVw>? MnzUTWM2ODxzIN88US=> MWOyOFg4QTd7Nh?=
HCC38 M3zLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPkVIUyKM7:TR?= NXjVdXlzPSCm M4K4O2ROW09? NUnqRYJPUUN3MEyxJO69VQ>? NE\yNnIzPDh5OUe5Oi=>
HCC1419 NGnqW45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPTfHMyKM7:TR?= MmqyOUBl MULEUXNQ M1;JXGlEPTB:MTFOwG0> M{XkW|I1QDd7N{m2
UACC-812 NUfvN243T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi2W3BZOSEQvF2= NG\GepQ2KGR? NXTNXWwxTE2VTx?= Ml25TWM2ODxzIN88US=> MXWyOFg4QTd7Nh?=
HCC1187 NXXrclBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP2VpcyKM7:TR?= NXm3UYh5PSCm Mk\aSG1UVw>? M3vkeGlEPTB:MTFOwG0> NV24RVFkOjR6N{m3PVY>
KPL-1 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7NNUDPxE1? NI\BSHE2KGR? M4PDfGROW09? M2ewe2lEPTB:MTFOwG0> NHjuUWEzPDh5OUe5Oi=>
SUM-225 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D6eFEh|ryP NX7Pc|dSPSCm NG\tOHpFVVOR M1vhVmlEPTB:MTFOwG0> M{nPcVI1QDd7N{m2
EFM-192A Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPuU4JTOSEQvF2= NUfOOm1QPSCm NGDxTHRFVVOR NWDabZlVUUN3MEyxJO69VQ>? M4\3dFI1QDd7N{m2
JIMT-1 NFTwelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSwOWF{OSEQvF2= NH7IcJM2KGR? M4r3bmROW09? NVzyT3ZMUUN3MEyxJO69VQ>? MV2yOFg4QTd7Nh?=
HCC1143 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfWOYg5OSEQvF2= M4nWT|Uh\A>? Mm\sSG1UVw>? NHHFV4NKSzVyPEGg{txO MVuyOFg4QTd7Nh?=
HCC2218 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQWVEh|ryP NXGyRY5lPSCm NGLkW5NFVVOR NUDmUpFkUUN3MEyxJO69VQ>? NYr5foxmOjR6N{m3PVY>
MDA-MB-468 NUjqS5QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmxSWsyKM7:TR?= M3rPOFUh\A>? NEHEcpRFVVOR MnvKTWM2ODxzIN88US=> NU\1dZJPOjR6N{m3PVY>
BT-20 M4T2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXGNUDPxE1? NEO2UVQ2KGR? NH7zUWpFVVOR M3zVSWlEPTB:MTFOwG0> NFPn[oUzPDh5OUe5Oi=>
MDA-MB-435 NHrPZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[xJO69VQ>? M4KzSVUh\A>? M1LJO2ROW09? M2\VT2lEPTB:MTFOwG0> M3m2XlI1QDd7N{m2
BT-549 M13te2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zSU|Eh|ryP M{\CeFUh\A>? NHnTd45FVVOR M3XJfWlEPTB:MTFOwG0> NHza[YkzPDh5OUe5Oi=>
HCC1806 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjHNUDPxE1? M3TqbFUh\A>? MUDEUXNQ MlvSTWM2ODxzIN88US=> MXKyOFg4QTd7Nh?=
HCC1937 M{nmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLlNUDPxE1? Mn7sOUBl MUDEUXNQ M2Dvb2lEPTB:MTFOwG0> NHjKSlgzPDh5OUe5Oi=>
Hs578T MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWexJO69VQ>? NYrpcVlVPSCm M4XGSWROW09? NVnMNHF2UUN3MEyxJO69VQ>? NGTkNm8zPDh5OUe5Oi=>
LN18 M1;uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHINlAh|ryP NGnJWWM4OiCq MULEUXNQ NVjnSJc5UUN3MEy1JO69VQ>? Mmq4NlQ4PDFyN{S=
LN229 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvrPWczOCEQvF2= NVvGXFlOPzJiaB?= NXv0dXA1TE2VTx?= M{npfmlEPTB:NTFOwG0> MWWyOFc1OTB5NB?=
LNZ308 NE[wZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGyNEDPxE1? NEnRVnk4OiCq M133NmROW09? MkPaTWM2ODx3IN88US=> NXLtUodnOjR5NEGwO|Q>
T98G MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOyNEDPxE1? MVW3NkBp MlmwSG1UVw>? M4\KU2lEPTB:NTFOwG0> MXSyOFc1OTB5NB?=
U87 MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWyNEDPxE1? MlvOO|IhcA>? NXSxOXgyTE2VTx?= NHzKV3RKSzVyPEWg{txO NFrPPGQzPDd2MUC3OC=>
LN18 M{\yXmZ2dmO2aX;uJGF{e2G7 MlGxOUDPxE1? NWjZdVcyOjRiaB?= MXvEUXNQ NVS3PW8zUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= NXvQUGZiOjR5NEGwO|Q>
LNZ308 NXnz[np3TnWwY4Tpc44hSXO|YYm= MUK1JO69VQ>? M4HSS|I1KGh? NGe0dnZFVVOR MYXJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtV NHrVWnUzPDd2MUC3OC=>
Saos-2 NHjPTXVHfW6ldHnvckBCe3OjeR?= M1Xxd|UxKM7:TR?= M1XvR|Q5KGh? NGfwRZFKdmirYnn0d{Bk\WyuIHnueoF{cW:w M3ywXFI1PzJ5Nk[w
MG-63 Ml7zSpVv[3Srb36gRZN{[Xl? MnPjOVAh|ryP MWK0PEBp MkXZTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? M1HrTVI1PzJ5Nk[w
SJSA-1 MVnGeY5kfGmxbjDBd5NigQ>? NFjxe3k2OCEQvF2= NHfKOoY1QCCq M3:5NmlvcGmkaYTzJINmdGxiaX72ZZNqd25? NFTuVnEzPDd{N{[2NC=>
Saos-2 M2Pnc2Z2dmO2aX;uJGF{e2G7 M4\0R|UxKM7:TR?= MljTOFghcA>? NEHrfHJKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v NYX2fZBQOjR5Mke2OlA>
MG-63 NGXiTFNHfW6ldHnvckBCe3OjeR?= NWfaV4hVPTBizszN MVu0PEBp NWXGUFNRUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? M4qyUFI1PzJ5Nk[w
SJSA-1 M{nkU2Z2dmO2aX;uJGF{e2G7 MkHNOVAh|ryP MlPOOFghcA>? M3frZmlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NHvNdVczPDd{N{[2NC=>
Saos-2 NH\FNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS1NEDPxE1? NHrZRlE1QCCq MXjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NFvPN2kzPDd{N{[2NC=>
MG-63 NHn5OYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zOVAh|ryP NUTIRmdZPDhiaB?= MlnMTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NHTHbFIzPDd{N{[2NC=>
SJSA-1 NYnYdVFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUWyeFRJPTBizszN MoXXOFghcA>? Mmn3TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MYeyOFczPzZ4MB?=
FaDu NVPWfoRlTnWwY4Tpc44hSXO|YYm= MXq1JO69VQ>? NUfvWopEOjRiaB?= MlX2SG1UVw>? MUHS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= MmnoNlQ3OzFzNEe=
EMT6 MX3GeY5kfGmxbjDBd5NigQ>? MkGyOUDPxE1? Mn7pNlQhcA>? M1PueWROW09? M325OnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u MkjwNlQ3OzFzNEe=
HCT116 Mlm4SpVv[3Srb36gRZN{[Xl? NXfUTpo1PSEQvF2= MX:yOEBp Mn\tSG1UVw>? M{PkSHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NHHxfpgzPDZ|MUG0Oy=>
U87 NEPDXpVHfW6ldHnvckBCe3OjeR?= NWK0Z|BiPSEQvF2= NV\FbI5NOjRiaB?= MmLQSG1UVw>? MortVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= MUSyOFY{OTF2Nx?=
GBM MlPiRZBweHSxc3nzJGF{e2G7 M1zaN|LPxE1? MUW0PIg> M2jRR2ROW09? MmjObY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> NV;Ob2xWOjR3MEC0PVI>
BON MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxMVXPxE1? MmPKO|Jp M4izTIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> NVm5XHB3OjR2NEO1NlM>
BON NVPIWphCSXCxcITvd4l{KEG|c3H5 M4SyU|EuPc7:TR?= M2T5clI1cA>? NXXiOHQ5cW6lcnXhd4V{KGGyb4D0c5Nqew>? Ml3lNlQ1PDN3MkO=
H1975 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jt[|AvOy17LkdOwG0> NYjQXXJyPzKq NWfwPXRzTE2VTx?= Moi4TWM2OD1zLkO4Oe69VQ>? MmS0NlQ{Ozd6NE[=
H1975 M4fvTWFxd3C2b4Ppd{BCe3OjeR?= MnPhNu69VQ>? NFf3SJYzPGh? NELsSJVFVVOR NV60[|BGcW6lcnXhd4V{KGGyb4D0c5NqeyC{YYTlJJNq\26rZnnjZY51dHl? M3jVcVI1OzN5OES2
T-ALL MnniRZBweHSxc3nzJGF{e2G7 MXTi[ZR4\WWwIEGuOEBidmRiNT6zJI1OKGG2IEK0bEBidmRiMD65JIFv\CB3LkWgcW0h[XRiNEjoJIlvKGSrZn\ldoVvfCClZXzsJIxqdmV? MlrhNlQhd3JiNEjo NFzjTZRFVVOR M3X1dYFn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz Mlv4NlQ{OTB5M{[=
BCR-ABL M2rTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzQNE4zPS1zMN88US=> M3fhdFRl M4j1NZNq\26rZnnjZY51dHliaX7obYJqfCClZXzsJJBzd2yrZnXyZZRqd25? M3Tmb|I1OjR2NkGy
LC-1/SQSF NHzhdHFHfW6ldHnvckBCe3OjeR?= MWmz{txO NIj6fGkzPGh? MV7EUXNQ NEXORVBl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw> MnrYNlM6QDByOUO=
Primary CLL cells MVPBdI9xfG:|aYOgRZN{[Xl? MUWxMVEx|ryP NYHjPG9GPDiq MlzxbY5lfWOnczDhdI9xfG:|aYOgbY4hS0yOIHPlcIx{KGmwZHXw[Y5l\W62IH;mJJBzd2ewb4P0bYMhdWG{a3Xydy=> MUKyN|g2ODhyNx?=
Primary CLL cells NFi0bVRMcW6jc3WgRZN{[Xl? M{fWT|LPxE1? MVizNI1qdg>? MWnk[YNz\WG|ZXSgVGk{UyCjY4Tpeol1gQ>? NVrLW5dYOjN6NUC4NFc>
Primary CLL cells NIW0fXpEgXSxdH;4bYMhSXO|YYm= MViy{txO NVz1e3VMOjSq MlfkbY5lfWOnczDj[YxtKGO7dH;0c5hq[2m2eR?= M{nPW|I{QDVyOEC3
human NSCLC cell lines NW\xZ4pHSXCxcITvd4l{KEG|c3H5 NFr2d44xNjF{NT20{txO MYiyOIg> NG\HSlBFVVOR M2TPZ2lEPTC|IILhcodmeyCocn;tJFAvPC1{zszN MlzYNlM2PjJ2N{K=
human HCC cell lines NUjhTm9XS2WubDD2bYFjcWyrdImgZZN{[Xl? Mlz2NE4xODVvMd88US=> MXO0PIg> NVnoXZdDUUN3ME2x{txO NFH4dJgzOzR6OUm5PS=>
Huh7 NFjSPJlMcW6jc3WgRZN{[Xl? MXWx{txO Mlq3OFhp MUDzbYdvce,ugXPhcpRtgSC{ZXT1Z4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDa4S= Mn3ONlM1QDl7OUm=
SK-HEP1 NF:4PHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LmVVEuOjEQvF2= MX[3Nog> MnvDSG1UVw>? NEXhN|dKSzVy78{cNe69VQ>? MXiyN|Q4QTF|Nh?=
786-0 M1O3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnPVFMyNTJyzszN M{HWNlczcA>? M2\KcGROW09? NH\OWG5KSzVy78{cNe69VQ>? MXKyN|Q4QTF|Nh?=
JVM2 MnK0R5l1d3SxeHnjbZR6KGG|c3H5 NVXUdokyOC5{LUKw{txO MkXaO|Jp MoXkSG1UVw>? NFThdnBKSzVyPUCuPe69VQ>? MoDYNlMzOzh4M{m=
EHEB NGr3[3lEgXSxdH;4bYNqfHliYYPzZZk> M1HkbVAvOi1{MN88US=> MXe3Nog> NVu5NmVITE2VTx?= MoXJTWM2OD1yLkhOwG0> MXyyN|I{QDZ|OR?=
MEC2 Mn3tR5l1d3SxeHnjbZR6KGG|c3H5 M1\aZVAvOi1{MN88US=> NEXUbHU4Omh? M2[2NGROW09? M3T2[2lEPTB;MD63{txO MoHjNlMzOzh4M{m=
primary B-CLL lymphocytes NVyyV5BDSXCxcITvd4l{KEG|c3H5 NHfBe3VKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n Mo\ENlRp M4XyN2ROW09? NXriRWhrUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>? Mki1NlMzOzh4M{m=
primary B-CLL lymphocytes MkDQT4lv[XOnIFHzd4F6 MWXJR|UxKG[xcjDlZYNpKHC{aX3hdpkh[2WubDDsbY5m MWqyOIg> Mn2zbY5pcWKrdIOgdFcxWz[NID[gOGUuSlBzIHX4dJJme3Orb36= NVfwWIlrOjN{M{i2N|k>
human NSCLC M124TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVKwMlUuOs7:TR?= M1LzXlczcA>? MmfqTWM2OD1zzszN NXzFVoxrOjJ5OEGzPVM>
human NSCLC NFPr[2tMcW6jc3WgRZN{[Xl? NHXtVHAy|ryP M2PYUFI1cA>? NUPEbFlUcW6qaXLpeJMhfGinIFHreE9uXE:UIIPp[45idGmwZzDwZZRpf2G7IHH0JFNpKGGodHXyJJRz\WG2bXXueC=> M3f1VlIzPzhzM{mz
Y1 cell line M3;YTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSwMlHPxE1xMd88US=> M37ZPVI1cA>? NGnWVmJFVVOR MWXpcohq[mm2czC2NQ+9jSClZXzsJJZq[WKrbHn0fUBqdiCPeXOtV4N1ei22cnHud4Zm[3SnZDDj[Yxtew>? NU\sbmVwOjJ4OUK5NFQ>
PIK3CA-mutant MCF7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfrS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1? NWLPRoIyPzKq M3vrdGdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P MVOyNlY2Ozl4Nx?=
PIK3CA-mutant MCF7 NXfGdHlpU2mwYYPlJGF{e2G7 MnX6TWM2OD1zMUVCtVNvVQ>? NYX3cZhSPzKq MY\JR|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:|cHjvdplt[XSrb36gcIV3\Wy| M2PnZVIzPjV|OU[3
MCF7-myr-Akt M3;QN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? M{P0PVczcA>? M3iwPWdKPTB;Mkm5xtE3QG6P78{MUGQ2OO,:nkGwMFAxOG6P M1fzS|IzPjV|OU[3
colon cancer cell lines MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO5RVIxNTFyzszN NIrPXZA4Omh? NHX6UplFVVOR M37BNWlEPTB;Md88US=> Ml[3NlI2PDN6NUe=
gastric cancer cell lines MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTKe3NLOC1zMN88US=> MW[3Nog> M1SzN2ROW09? NGi5ZZpKSzVyPUKtOe69VQ>? NWXYbmg{OjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 MX7BdI9xfG:|aYOgRZN{[Xl? M3;lT|LPxE1? MkLNOFhp MXXzbIlnfCCrbjDHNkBxcGG|ZR?= NYDqV|JPOjJ3NEO4OVc>
HT-29 and HCT-116 M3vUZWNie3Cjc3WgZZN{[Xl? NYTHWYtHPc7:TR?= M2LWe|I1cA>? NF;TcHlqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm= NGHkdnQzOjV2M{i1Oy=>
MM cell lines NFPncHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTyNVDPxE1? NF3MbogzPGh? M4\hUGROW09? MmnOTWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm NHnaSGUzOjJyN{S4OS=>
ARP-1 NEe2UoRCeG:ydH;zbZMhSXO|YYm= NGDCSoMyOM7:TR?= Ml;PNlRp MXfEUXNQ Ml;TbY5lfWOnczDNUUBk\WyuIHHwc5B1d3OrczD0bJJwfWeqIHPhd5Bie2ViYXP0bZZifGmxbh?= MmrtNlIzODd2OEW=
SNU-601 NV3rXYtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3Nog> MnLrSG1UVw>? NFTFUolKSzVyPUCuPFE3yrFyLkC2N:69VQ>? MXqyNlE2QThzNB?=
SNU-1 M{\TTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;vO|Jp M3iwTGROW09? NVXVTHdNUUN3ME2xMlA5OsLzMD6wNljPxE1? MXWyNlE2QThzNB?=
SNU-668 NWr5[4dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3Nog> NYjBUmU1TE2VTx?= M2XobWlEPTB;MT61O|nDuTBwMEe0{txO MVuyNlE2QThzNB?=
AGS NVvHOYFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe5emNuPzKq NXmxc3RkTE2VTx?= M2DDPWlEPTB;MT63NVTDuTBwMUG3{txO NIXN[FUzOjF3OUixOC=>
SNU-216 M{H5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojmO|Jp NUnH[IRETE2VTx?= MonMTWM2OD1{Lk[5NuKyOC5yOENOwG0> NXXSbVJ7OjJzNUm4NVQ>
SNU-5 NVLNcVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j3V|czcA>? M3G0RmROW09? Mlj1TWM2OD1zLkO1NeKyOC5yOUJOwG0> NFmyXmszOjF3OUixOC=>
SNU-638 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYm3Nog> M175NGROW09? MXfJR|UxRTJwMkiyxtExNjB3M988US=> M{jRSFIzOTV7OEG0
SNU-16 NWLP[opST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn4[Hc4Omh? NUK4W2kxTE2VTx?= NV72WGhwUUN3ME2xMlU4O8LzMD6wNFHPxE1? NWKwcmFWOjJzNUm4NVQ>
SNU-484 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnKO|Jp NHXZcXlFVVOR NXLkZ2ZTUUN3ME2xMlczQMLzMD6wOFXPxE1? MWqyNlE2QThzNB?=
SNU-620 NGTOXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X3[|czcA>? NULDdY42TE2VTx?= MX3JR|UxRTJwOUO5xtExNjByMd88US=> NYDoeppXOjJzNUm4NVQ>
SNU-719 NE\lNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P6UlczcA>? NWj3V4c{TE2VTx?= M1nQeWlEPTB;Mz6wN|fDuTBwMEOy{txO NF;Ee4szOjF3OUixOC=>
glioma cell lines MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3Nog> NFHuN5ZKSzVyPUGtNu69VQ>? NYX0cIFWOjJyNkWwPFA>
U87 NUnGc4ZYSXCxcITvd4l{KEG|c3H5 NGnvPVMz|ryP NUDwcI12PzKq MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?= Ml;6NlIxPjVyOEC=

... Click to View More Cell Line Experimental Data

In vivo試験 BKM120 completely inhibits pAktser473 in A2780 xenograft tumors at doses of 30, 60, or 100 mg/kg, respectively. BKM120 also shows antitumor activity against U87MG glioma model at doses of 30 and 60 mg/kg. [1] BKM120 treatment results in significantly reduced tumor volume and level of circulating human kappa chain at 5 μM/kg/day−1in ARP1 SCID mouse model, with prolonged survival. [2]
臨床試験 Current under Phase II in men with metastatic castration-resistant prostate cancer.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

PI3K biochemical assay (ATP depletion assay) BKM120 is dissolved in DMSO and directly distributed into a black 384-well plate at 1.25 µL per well. To start the reaction, 25 µL of 10 nM PI3 kinase and 5 µg/mL 1-α-phosphatidylinositol (PI) in assay buffer (10 mM Tris pH 7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT and 0.05% CHAPS) are added into each well followed by 25 µL of 2 µM ATP in assay buffer. The reaction is performed until approx 50% of the ATP is depleted and then stopped by the addition of 25 µL of KinaseGlo solution. The stopped reaction is incubated for 5 minutes and the remaining ATP is then detected via luminescence.
PI3K biochemical assay (filter binding assay) 50 µL/well of a 1:1 mixture of 100 µL/mL L-α-phosphatidylinositol and L-α-phosphatidylserine dissolved in chloroform:ethanol (2.2:7.8) is pipetted into 96-well MaxiSorpTM plates. The solvents are evaporated at room temperature and plates are wa

細胞アッセイ: [1]

細胞株 A2780 cells.
濃度 0-6.6 μM
反応時間 3 days.
実験の流れ A2780 cells are cultured in DMEM supplemented with 10% FBS, L-glutamine, sodium pyruvate, and antibiotics. Cells are plated in the same medium at a density of 103 cells per well, 100 μL per well into black-walled-clear-bottom plates and incubated for 3-5 hours. BKM120 supplied in DMSO (20 mM) is diluted. The diluted BKM120 solution (2 μL), is then added to cell medium (500 μL) cell medium (concentration from 0-6.6 μM). Equal volumes of this solution (100 μL) are added to the cells in 96 well plates and incubated at 37 °C for 3 days and developed using Cell Titer Glo. Inhibition of cell proliferation is determined by luminescence read using Trilux.

動物実験: [1]

動物モデル U87MG and A2780 xenografts are established in female nu/nu mice.
製剤 In 15% Captisol.
投薬量 ~60 mg/kg.
投与方法 Dosed orally daily (q.d.).

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download BKM120 (NVP-BKM120, Buparlisib) SDF
分子量 410.39
化学式

C18H21F3N6O2

CAS No. 944396-07-0
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 82 mg/mL (199.8 mM)
エタノール 2 mg/mL (4.87 mM)
<1 mg/mL (<1 mM)
In vivo 0.5% CMC Na 6 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine

文献中の引用 (34)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

最近チェックしたアイテム

Tags: BKM120 (NVP-BKM120, Buparlisib)を買う | BKM120 (NVP-BKM120, Buparlisib)供給者 | BKM120 (NVP-BKM120, Buparlisib)を購入する | BKM120 (NVP-BKM120, Buparlisib)費用 | BKM120 (NVP-BKM120, Buparlisib)生産者 | オーダーBKM120 (NVP-BKM120, Buparlisib) | BKM120 (NVP-BKM120, Buparlisib)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ